License negotiation between Ambrilia Biopharma Inc. and Merck & Co.

Client

Ambrilia Biopharma Inc.
Member of the license negotiation team (clinical phase 1) between Ambrilia Biopharma Inc. and Merck & Co. (reported value: $232,000,000)